By Infinium Global Research Aug, 2020
The Global Non-hodgkin Lymphoma Treatment Market is expected to grow at a CAGR of 7.20% between 2019 and 2025 in terms of value. The growing prevalence of non-Hodgkin lymphoma cancers are driving the growth of the non-Hodgkin lymphoma treatment market. The American Cancer Society estimates that 74,200 cases of non-Hodgkin lymphoma will be diagnosed in 2019. Furthermore, rapidly expanding elderly population is anticipated to boost the market growth as majority of patients with non-Hodgkin lymphoma are over the age of 60. In addition, growing number of clinical trials for the development of new drugs and the launch of several novel drugs for the treatment of non-Hodgkin lymphoma are anticipated to propel the growth of the non-Hodgkin lymphoma treatment market. Several major manufacturers are focusing on the development of new products for the treatment of Non-Hodgkin lymphoma (NHL), which in turn will boost the market growth over the forecast period. However, high cost associated with the treatment of non-Hodgkin lymphoma is likely to hamper the growth of the non-Hodgkin lymphoma treatment market. In addition, expiry of several standard drugs are expected to create lucrative opportunities for the emerging market players in the non-Hodgkin lymphoma treatment market.
The incidence of non-Hodgkin lymphoma (NHL) varies by geographic region. The areas with the highest incidence of NHL are North America, Europe, and Australasia, as well as several countries in Africa and South America. North America accounts for the largest revenue in the global non-Hodgkin lymphoma treatment market. The high prevalence of non- Hodgkin lymphoma contributes to the growth of the market. The disease accounts for 4% of all cancers in the United States. Furthermore, well established healthcare infrastructure, favorable reimbursement policies and high spending capacity of the people in North American countries such as the U.S. and Canada favors the growth of the market in this region. Europe is anticipated to hold the second largest share in the total addressable market owing to factors such as increasing cases of B-Cell lymphoma, rising aging population and growing number in the clinical trials for the treatment of NHL treatment market in this region.